Jasper Therapeutics (JSPR) Research & Development (2020 - 2025)

Jasper Therapeutics has reported Research & Development for 6 years, with the latest figure at $11.4 million in Q4 2025.

• On a quarterly basis, Research & Development fell 42.55% year-over-year to $11.4 million in Q4 2025; TTM through Dec 2025 was $63.1 million, a 13.05% increase from a year earlier, with the FY2025 full-year figure at $63.1 million, up 13.05% from the prior year.
• Research & Development was $11.4 million for Q4 2025 at Jasper Therapeutics, down from $14.4 million in the prior quarter.
• The five-year high for Research & Development was $21.2 million in Q2 2025, with the low at $842000.0 in Q4 2022.
• Average Research & Development over 5 years is $11.1 million, with a median of $10.8 million recorded in 2024.
• The sharpest annual moves came in 2021 and 2022: Research & Development surged 4790.96% in 2021, then tumbled 90.27% in 2022.
• Over 5 years, Research & Development stood at $8.7 million in 2021, then sank by 90.27% to $842000.0 in 2022, then surged by 1543.11% to $13.8 million in 2023, then jumped by 42.91% to $19.8 million in 2024, then slumped by 42.55% to $11.4 million in 2025.
• The last three Research & Development figures came in at $11.4 million (Q4 2025), $14.4 million (Q3 2025), and $21.2 million (Q2 2025), per Business Quant data.